MedTrace Logo

Stem Cell Study for Long COVID-19 Neurological Symptoms

NCT06156241 · Status: NOT_YET_RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 12

Last updated 2023-12-05

No results posted yet for this study

Summary

The purpose of this research study is to test the safety and benefit of a human cord blood derived stem cell infusion as a treatment for individuals with post COVID-19 neurological problems. Participants in the study will have 6 clinic visits over a 12 to 14 mo. period with each visit lasting 2 to 6 hours. Participants will receive 1 stem cell infusion at study visit #3. Participants will have a brain PET and MRI scan at the baseline and 6mo. post-infusion visits. Follow-up safety assessments will be conducted at 6mo. and 1yr. after the stem cell infusion.

Conditions

  • Post-Acute COVID-19 Syndrome

Interventions

BIOLOGICAL

Stem Cell

Stem cells derived from human cord tissue.

Sponsors & Collaborators

  • CBR Systems, Inc.

    collaborator OTHER

  • Charles Cox

    lead OTHER

Principal Investigators

  • Charles S. Cox, MD · The Univ. of Tx. Health Science Center- Houston

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-01-31
Primary Completion
2025-12-31
Completion
2026-02-28
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06156241 on ClinicalTrials.gov